Bill restores Medicaid savings but shields orphan drugs from price negotiation

What it does

This bill repeals two provisions from a 2024 reconciliation law (Public Law 119–21). First, it undoes changes to Medicaid cost-sharing rules that were tightened in that law, restoring the prior Medicaid cost-sharing framework. Second, it repeals changes to the Medicare Drug Price Negotiation Program that had excluded orphan drugs (rare-disease medications), restoring the prior exclusion. The bill also rescinds appropriations tied to the Medicaid cost-sharing changes.

Why we flagged it

The bill's core mechanism is a two-part repeal: it restores Medicaid cost-sharing protections (a public-benefit move) while simultaneously restoring an orphan-drug pricing exemption (a private-benefit move favoring pharmaceutical manufacturers). The net effect is mixed — one arm helps patients, the other shields drug makers from price negotiation.

What the text implies

• Restoring the orphan-drug exclusion from Medicare negotiation may increase federal spending on rare-disease treatments, as Medicare loses negotiating leverage on a category of high-cost drugs.
• The bill's title ('Protect Patients from Costly Care') emphasizes the Medicaid cost-sharing restoration but does not disclose the orphan-drug exemption restoration, creating a framing asymmetry.
• Patients with rare diseases covered by Medicare may face higher out-of-pocket costs or formulary restrictions if manufacturers maintain elevated prices outside negotiation.
• The rescission of appropriations under Section 71120(c) may reduce federal funding available for Medicaid administration or enforcement of the prior cost-sharing rules.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Restoring prior Medicaid cost-sharing rules benefits low-income patients by reducing out-of-pocket costs for essential care. However, restoring the orphan-drug exclusion from Medicare price negotiation means patients and Medicare pay higher prices for rare-disease treatments, offsetting the Medicaid benefit for those conditions and raising costs for seniors and the program overall.

Who stands to gain

• pharmaceutical manufacturers (orphan-drug producers)
• specialty pharmaceutical companies

Named in the bill

Centers for Medicare & Medicaid Services (CMS), Medicaid, Medicare, Drug Price Negotiation Program, Public Law 119–21, Social Security Act (Title XIX, Title XI), orphan drugs

Where it stands

9 cosponsors: 9 Democrats.

• Sep 2, 2025 — Introduced · Congress.gov: “Introduced in House”
• Sep 2, 2025 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $10,000 in lobbying spend. A filing names 2 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Chris Pappas, the sponsor, reported $1,125,432 in PAC receipts in the 2026 cycle.

• Agios Pharmaceuticals — $10,000 on 1 filing

Lobbying Disclosure Act filings through Jul 16, 2026. A filing shows who paid to lobby on a bill it names, not what changed.